1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Exopharm Limited
  6. Company
    EX1   AU0000030975


Delayed Australian Stock Exchange  -  05/15 10:15:40 pm EDT
0.1750 AUD   -2.78%
02/25EXOPHARM : Appendix 4D and Half Year Report for period 31 December 2021
02/24Exopharm Limited Reports Earnings Results for the Half Year Ended December 31, 2021
02/03EXOPHARM : Response to ASX Query
Business Summary
Exopharm Limited is an Australia-based company, which is engaged in transformative medicines using exosomes or extracellular vesicles (EVs) and is also engaged in product pipeline-driven platform strategy. The Company's principal activities include pipeline products analysis and selection; technology development and validation; and commercial collaborations. The Company operates through regenerative medicine and biopharmaceutical drug development segment. Its exosome technologies solve the needs for the success of exosome medicines. Its technologies include LEAP manufacturing technology, LOAD active pharmaceutical ingredients (APIs) loading technologies, and EVPS tropism technologies. The Company is developing Engineered EVs (EEVs), an emerging form of precision medicine with application in areas, such as neurology, cardiology, and oncology. Its EEV technology includes EVPS to provide tissue tropism to exosomes and LOAD to load in APIs, such as messenger ribonucleic acid (mRNA).

Number of employees : 41 people.
Name Title Age Since
Ian Dixon, Dr. Chief Executive Officer, Director & MD - 2013
Gregor Lichtfuss, Dr. Chief Operating Officer - 2013
David James Franks Secretary 50 2021
Christopher Baldwin, Dr. Chief Commercial Officer & Deputy CEO - 2021
Alison Jane Mew Director-Manufacturing & Development 63 2020
Aislinn Treloar Head-Business Development - -
Members of the board
Name Title Age Since
Jason Watson Non-Executive Chairman - 2018
Jennifer King, Dr. Independent Non-Executive Director - 2021
Ian Dixon, Dr. Chief Executive Officer, Director & MD - 2013
Elizabeth McGregor Non-Executive Director - 2021
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 157,211,533 91,057,254 57.9% 0 0.0% 57.9%
Altnia Holdings Pty Ltd. 28,258,627 18.0%
Carl Charalambous 13,786,272 8.77%
Kohen Enterprises Pty Ltd. 2,002,000 1.27%
Paul Joseph Cozzi 2,000,000 1.27%
Michael Francis Mcmahon 1,635,849 1.04%
Oldview Agriculture Pvt Ltd. 1,610,000 1.02%
Development Management & Consulting Group, Inc. 1,545,350 0.98%
Russell Neil Creagh 1,457,000 0.93%
Peter Dallas Checkley 1,410,275 0.90%
Norman Cipriano 1,312,500 0.83%
Company contact information
Exopharm Ltd.
Level 17/31 Queen Street
Melbourne, Victoria (VIC) 3000

Phone : +61.3.9111.0026
Web : http://www.exopharm.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of Exopharm Limited